VTE Registry: What Can Be Learned from RIETE?
The Registro Informatizado de Enfermedad TromboEmbólica (RIETE Registry) is an ongoing, international, prospective registry of consecutive patients with acute venous thromboembolism (VTE) designed to gather and analyze data on treatment patterns and outcomes in patients with acute VTE. It started in Spain in 2001, and 6 years later the database was translated into English with the aim to expand the Registry to other countries. In contrast to randomized controlled trials, there is no imposed experimental intervention: the management is determined solely by physicians. Thus, it provides data on patients with VTE in a real-world situation with an unselected patient population. Data from RIETE are hypothesis-generating and provide feedback from real-world clinical situations. So far, we learned about the natural history of VTE in patients with relative or absolute contraindications to anticoagulant therapy. We also learned interesting aspects on the natural history of VTE, and we built a number of prognostic scores to identify VTE patients at low, moderate, or high risk for adverse outcome.
Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel;
Inna
I
Tzoran
Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel; ; Bruce Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, Haifa, Israel;
Benjamin
B
Brenner
Department of Hematology, Hospital Papageorgion, Saloniki, Greece;
Manolis
M
Papadakis
Department of Internal Medicine, Ospedale Buon Consiglio Fatebenefratelli, Naples, Italy.
Pierpaolo
P
Di Micco
Department of Internal Medicine, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
Manuel
M
Monreal
Anticoagulant therapy; outcome; registry; venous thromboembolism